Final report of a randomized controlled study with streptococcal preparation OK-432 as a supplementary immunopotentiator for laryngeal cancer.

Final report of a randomized controlled study with streptococcal preparation OK-432 as a supplementary immunopotentiator for laryngeal cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Final report of a randomized controlled study with streptococcal preparation OK-432 as a supplementary immunopotentiator for laryngeal cancer. Abstract Text:

T Kimura,K Suzuki,H Motai,N Miyamoto,I Tsuge,Y Ito,S Baba,

We conducted a randomized controlled study of streptococcal preparation OK-432 on 120 newly identified cases of laryngeal squamous cell carcinoma who were registered at 10 participating institutions between November 1984 and October 1989. The patients were divided into two groups: those in early stages (stage I or II) and those in advanced stages (stage III or IV); these groups were further subdivided into an immunotherapy group (receiving OK-432) and a control group (who did not receive OK-432). The usefulness of OK-432 was studied using the sealed envelope method. The basic therapy for all cases was radiotherapy and, when required, surgery. As adjuvant therapy, 5Fu or derivatives were administered to all cases from the beginning of the treatment period to one year after the basic therapy, with the exception of cases in whom side effects were serious enough to contraindicate use of the drug. The target administration period was 5 years. Of the initial 120 cases, 11 cases were disqualified (3 cases of double cancer and 8 of incomplete primary therapy) and the remaining 109 were used for evaluation. The 5-year survival rate and the 5-year recurrence-free rate were 76% and 84%, respectively, in the immunized groups (both the early and advanced groups), whereas the same rates for the control groups were 78% and 75%. There was a tendency for the immunized groups to enjoy a slightly longer recurrence-free period. Over a 24-month observation period the immunized group always had higher levels of peripheral leukocytes and peripheral lymphocytes; this difference was significant for the first 21 months. Inhibition of bone marrow function is sometimes observed with radiotherapy. It is hoped that, if this inhibition can be mitigated, it will be possible to assist the compromised immune system and maintain a certain level of immune performance which will prevent recurrence and improve survival rate. In the present study we observed a tendency of the lower recurrence rate in the immunized group, and we hypothesize that OK-432 is effective in extending the recurrence-free period.

Final report of a randomized controlled study with streptococcal preparation OK-432 as a supplementary immunopotentiator for laryngeal cancer. Publishing Authors By Initials

T Kimura,K Suzuki,H Motai,N Miyamoto,I Tsuge,Y Ito,S Baba,

For similar investigative techniques: epidemiologic methods: data collection: vital statistics: mortality: survival rate research abstracts see: investigative techniques: epidemiologic methods: data collection: vital statistics: mortality: survival rate research

PUBMED ID PMID:

MEDLINE DATE:

Final report of a randomized controlled study with streptococcal preparation OK-432 as a supplementary immunopotentiator for laryngeal cancer. Journal Published:

PUBLICATION TYPE: Randomized Controlled Trial

Journal: Acta oto-laryngologica. Supplementum

VOLUME: 525

Page Numbers: 135-41

Journal Abbreviation:

ISSN: 0365-5237

DAY: 13

MONTH: 02

YEAR: 1996

Final report of a randomized controlled study with streptococcal preparation OK-432 as a supplementary immunopotentiator for laryngeal cancer. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 370355

Final report of a randomized controlled study with streptococcal preparation OK-432 as a supplementary immunopotentiator for laryngeal cancer. Keywords Mesh Terms:

KEYWORDS: Survival Rate

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Final report of a randomized controlled study with streptococcal preparation OK-432 as a supplementary immunopotentiator for laryngeal cancer. Information

Substance Name: Picibanil

Registry Number: 39325-01-4

Grant and Affiliation Information for Final report of a randomized controlled study with streptococcal preparation OK-432 as a supplementary immunopotentiator for laryngeal cancer.

AFFILIATION: Department of Otorhinolaryngology, Nagoya City University Medical School, Japan.

Country: NORWAY

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Acta Otolaryngol Suppl

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Final report of a randomized controlled study with streptococcal preparation OK-432 as a supplementary immunopotentiator for laryngeal cancer Related Publications

• Charging dynamics of the electric double layer in porous media.
• Cloning and functional expression of cycloartenol synthases from mangrove species Rhizophora stylosa Griff. and Kandelia candel (L.) Druce.
• Comparison of intrahepatic and pancreatic perfusion on fusion images using a combined SPECT/CT system and assessment of efficacy of combined continuous arterial infusion and systemic chemotherapy in advanced pancreatic carcinoma.
• Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) blocks the chemotaxis of neutrophils by inhibiting signal transduction through IL-8 receptors.
• Detection of a mixed infection of a novel Cryptosporidium andersoni and its subgenotype in Japanese cattle.
• Dipole-LUMO/dipolarophile-HOMO controlled asymmetric cycloadditions of carbonyl ylides catalyzed by chiral Lewis acids.
• Effects of Salmonella enterica subsp. enterica serovar Enteritidis vaccination in layer hens subjected to S. Enteritidis challenge and various feed withdrawal regimens.
• Efficacy of etanercept in patients with AA amyloidosis secondary to rheumatoid arthritis.
• Embryogenesis and swimming behavior of Medaka fish in JUSTSAP STARS Program (STS-107).
• Experiences in quality assurance at Bawku Hospital Eye Department, Ghana.
• Gemcitabine and paclitaxel chemotherapy as a second-line treatment for advanced or metastatic urothelial carcinoma.
• InCl3/I2-catalyzed cross-coupling of alkyl trimethylsilyl ethers and allylsilanes via an in situ derived combined Lewis acid of InCl3 and Me3SiI.
• Induction of interleukin-8 (CXCL-8) by tumor necrosis factor-alpha and leukemia inhibitory factor in pancreatic carcinoma cells: Impact of CXCL-8 as an autocrine growth factor.
• Low-group-velocity and low-dispersion slow light in photonic crystal waveguides.
• Ossification of the posterior longitudinal ligament of the cervical spine: histopathological findings around the calcification and ossification front.
• Pituitary adenylate cyclase-activating polypeptide is associated with schizophrenia.
• Posterior 360-degree stabilisation of the upper thoracic spine: a technical note.
• Potent and selective inhibition of Tat-dependent HIV-1 replication in chronically infected cells by a novel naphthalene derivative JTK-101.
• Predictive factors for platelet increase after partial splenic embolization in liver cirrhosis patients.
• Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases.
• Quantitative gait analysis of patients with bilateral hip osteoarthritis excluding the influence of walking speed.
• Sensory aphasia after closed head injury.
• Single-molecule measurements with a single quantum dot.
• The red eye - first aid at the primary level.
• Thoracic ossification of the human ligamentum flavum: histopathological and immunohistochemical findings around the ossified lesion.
• X-ray absorption beamline at the Mitsubishi compact storage ring.
• [Circadian rhythm monitoring in an individual animal]
• [High-normal blood pressure]
• [Molecular pharmacologic approaches to functional analysis of new biological target molecules for drug discovery]
• [Studies on chemical constituents from roots of Peucedanum praeruptorum II]